Novel MASH Drug Reduces Liver Fat in Mid-Stage Trial

(MedPage Today) -- BOSTON -- Treatment with an investigational thyroid hormone receptor-beta (THR-β) agonist significantly reduced liver fat content in patients with metabolic dysfunction-associated steatohepatitis (MASH), a placebo-controlled...
Source: MedPage Today Gastroenterology - Category: Gastroenterology Source Type: news